Bristol Company Profile

✉ Email this page to a colleague

BRISTOL has one hundred and eighteen approved drugs.

There are fifty-seven US patents protecting BRISTOL drugs.

There are one thousand seven hundred and thirty-seven patent family members on BRISTOL drugs in fifty-eight countries and three hundred and twenty supplementary protection certificates in nineteen countries.

International Patents:	1737
US Patents:	57
Tradenames:	95
Ingredients:	83
NDAs:	118
Drug Master File Entries:	1
Patent Litigation for Bristol:	See patent lawsuits for Bristol
PTAB Cases with Bristol as patent owner:	See PTAB cases with Bristol as patent owner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	ONUREG	azacitidine	TABLET;ORAL	214120-002	Sep 1, 2020		RX	Yes	Yes	11,571,436	⤷ Sign Up	Y			⤷ Sign Up
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-002	Mar 25, 2020		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Bristol Myers Squibb	METAGLIP	glipizide; metformin hydrochloride	TABLET;ORAL	021460-003	Oct 21, 2002		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Bristol	PRECEF	ceforanide	INJECTABLE;INJECTION	050554-003	May 24, 1984		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-003	Jun 28, 2006	AB	RX	Yes	No	8,680,103*PED	⤷ Sign Up			Y	⤷ Sign Up
Bristol Myers Squibb	STILBESTROL	diethylstilbestrol	SUPPOSITORY;VAGINAL	004056-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	7,189,740	⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005	8,626,531	⤷ Sign Up
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998	6,561,977	⤷ Sign Up
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	7,435,745	⤷ Sign Up
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	7,959,566	⤷ Sign Up
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	7,723,361	⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	9,056,120	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	150 mg	➤ Subscribe	2014-02-03
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Injection	10 mg/vial	➤ Subscribe	2013-11-05
➤ Subscribe	Capsules	100 mg and 150 mg	➤ Subscribe	2010-03-19
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2009-04-09
➤ Subscribe	Nasal Spray	4 mg/spray	➤ Subscribe	2016-07-15
➤ Subscribe	Tablets	2.5 mg and 5 mg	➤ Subscribe	2016-12-28
➤ Subscribe	Tablets	20 mg, 50 mg, 70 mg and 100 mg	➤ Subscribe	2010-06-28
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-17
➤ Subscribe	Delayed-release Capsules	200 mg, 250 mg and 400 mg	➤ Subscribe	2004-06-01
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2006-09-25
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30
➤ Subscribe	For Injection Suspension	100 mg/vial	➤ Subscribe	2015-12-11
➤ Subscribe	Capsules	300 mg	➤ Subscribe	2009-07-20
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2010-02-16
➤ Subscribe	Capsules	50 mg, 100 mg and 200 mg	➤ Subscribe	2016-11-03
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-06-14
➤ Subscribe	Tablets	30 mg	➤ Subscribe	2005-06-01
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-16
➤ Subscribe	Capsules	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2017-02-08
➤ Subscribe	Capsules	50 mg and 100 mg	➤ Subscribe	2006-12-18
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1427415	122011100050	Germany	⤷ Sign Up	PRODUCT NAME: APIXABAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/691/001-005 20110518
1304992	C01304992/01	Switzerland	⤷ Sign Up	PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
3150586	PA2020508	Lithuania	⤷ Sign Up	PRODUCT NAME: KOBICISTANAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS, DARUNAVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS, YPAC DARUNAVIRO ETANOLATAS, IR EMTRICITABINAS, ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/17/1225 20170921
2049506	2015/058	Ireland	⤷ Sign Up	PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/830/001-EU/1/13/830/002 20130524
1169038	1390004-8	Sweden	⤷ Sign Up	PRODUCT NAME: DASATINIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/06/363/001 20061120
2922846	122023000049	Germany	⤷ Sign Up	PRODUCT NAME: DEUCRAVACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1718 20230324
2105135	C20150005 00140	Estonia	⤷ Sign Up	PRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.